StreetInsider.com News Articles

Amarin presents new REDUCE-IT data at ESC Congress 2026

Mon, 31 Aug 2026 08:15:53 -0400

Amarin Corporation (NASDAQ: AMRN) highlighted findings from multiple company-supported research presentations at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, covering treatment adherence, cardiovascular outcomes, lipoprotein(a), coagulation biomarkers, and potential mechanisms of eicosapentaenoic acid (EPA).

A post hoc analysis of REDUCE-IT examined lipoprotein(a) [Lp(a)] variability over 24 months among 5,036 of the trial's 8,179 participants. Investigators found substantial variability in Lp(a) levels over time, particularly in patients with higher baseline concentrations. Participants with average Lp(a) levels of 70 mg/dL or higher showed a mean within-patient range of 25.3 mg/dL, and more than one-third of participants with baseline Lp(a)

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

Mon, 31 Aug 2026 08:15:00 -0400

Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)

2026 ESC/European Renal Association (ERA) Cardiovascular and Chronic Kidney Disease Guideline Further Reinforces the Clinical Evidence Supporting Icosapent Ethyl

DUBLIN and BRIDGEWATER, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted findings from multiple Amarin supported presentations at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. The research presented by leading academic collaborators further expanded

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

Mon, 31 Aug 2026 08:15:00 -0400

Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)

2026 ESC/European Renal Association (ERA) Cardiovascular and Chronic Kidney Disease Guideline Further Reinforces the Clinical Evidence Supporting Icosapent Ethyl

Amarin presents REDUCE-IT legacy analysis at ESC Congress 2026

Fri, 28 Aug 2026 08:16:55 -0400

Amarin Corporation (NASDAQ: AMRN) presented a new post hoc analysis from the REDUCE-IT cardiovascular outcomes trial at the European Society of Cardiology Congress 2026 in Munich, Germany, on Aug. 28, 2026.

The analysis examined the relationship between treatment adherence and cardiovascular outcomes among patients treated with icosapent ethyl (IPE), as well as whether cardiovascular benefits persisted after treatment discontinuation.

Among the 8,179 participants enrolled in REDUCE-IT, the intention-to-treat analysis showed a 25% relative risk reduction in the primary composite endpoint with IPE versus placebo. Among participants who remained on the study drug for at least 1.5 years, defined as high adherers and

Amarin presents REDUCE-IT legacy analysis at ESC Congress 2026

Fri, 28 Aug 2026 08:16:55 -0400

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Pat

Fri, 28 Aug 2026 08:15:00 -0400

Data Supports Approximately 30% Relative Risk Reduction Among Highly Adherent Patients and Provides Evidence Consistent with a Potential Legacy Effect in Secondary Prevention Patients After Treatment Discontinuation

DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT^® cardiovascular outcomes trial, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. The analysis showed that highly adherent participants who remained on icosapent ethyl (IPE) treatment for at least 1.5 years experienced

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Pat

Fri, 28 Aug 2026 08:15:00 -0400

Amarin to present REDUCE-IT analyses at ESC Congress 2026

Mon, 24 Aug 2026 08:17:12 -0400

Amarin Corporation (NASDAQ: AMRN) announced it will present five research abstracts at the European Society of Cardiology Congress 2026, scheduled for Aug. 28–31 in Munich, Germany.

The presentations, supported by Amarin and delivered by international academic collaborators, draw on data from the REDUCE-IT cardiovascular outcomes trial and related mechanistic research involving icosapent ethyl, also known as eicosapentaenoic acid (EPA).

Four moderated poster presentations are scheduled. Topics include treatment adherence and legacy effects of high-dose EPA in patients with hypertriglyceridemia and high cardiovascular risk; sex differences in early study discontinuation and drug withdrawal within REDUCE-IT; effects of icosapent ethyl on coagulation biomarkers and

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

Mon, 24 Aug 2026 08:15:00 -0400

DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, August 28^t^h- 31^st, in Munich, Germany.

The accepted abstracts add to the body of evidence generated from REDUCE-IT and related research investigating cardiovascular risk factors, biomarkers and potential mechanisms associated with the effects of icosapent ethyl or eicosapentaenoic acid (EPA). The presentations include analyses of treatment adherence, long-term outcomes, lipoprotein(a) [Lp(a)], coagulation biomarkers and cellular pathways

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

Mon, 24 Aug 2026 08:15:00 -0400

JPMorgan Reinstates Amarin Corporation (AMRN) at Underweight

Fri, 21 Aug 2026 03:28:19 -0400

JPMorgan analyst Jessica Fye reinstates coverage on Amarin Corporation (NASDAQ: AMRN) with a Underweight rating and a price target of $13.00.

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $14.06 yesterday.

Form 4 AMARIN CORP PLC\UK For: Aug 01 Filed by: Fishman Peter L.

Mon, 03 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260803/26858522.html

Form 4 AMARIN CORP PLC\UK For: Aug 01 Filed by: Fishman Peter L.

Mon, 03 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260803/26858522.html

Amarin Corp. (AMRN) Reports In-Line Q2 EPS

Wed, 29 Jul 2026 07:26:54 -0400

Amarin Corp. (NASDAQ: AMRN) reported Q2 EPS of $0.00. Revenue for the quarter came in at $42.2 million.

For earnings history and earnings-related data on Amarin Corp. (AMRN) click here.

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Wed, 29 Jul 2026 07:00:00 -0400

Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow

For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA’s U.S. Market Share, an Improved OPEX Profile, and Positive Cash Flow Generation

DUBLIN, Ireland and BRIDGEWATER, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the second quarter ended June 30, 2026 (Q2 2026) and highlighted positive outlooks associated with the

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Wed, 29 Jul 2026 07:00:00 -0400

Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow

For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA’s U.S. Market Share, an Improved OPEX Profile, and Positive Cash Flow Generation

Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Provoost Jonathan